Drug Profile
MLN 3126
Alternative Names: MLN3126Latest Information Update: 19 May 2015
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals
- Developer Takeda
- Class Anti-inflammatories; Small molecules
- Mechanism of Action CCR9 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Sjogren's syndrome
Most Recent Events
- 19 May 2015 Discontinued - Phase-I for Sjogren's syndrome in USA (PO)
- 17 May 2015 Takeda terminates a phase I trial in Healthy volunteers in USA (NCT02447458)
- 01 Sep 2013 Takeda initiates enrolment in a phase I trial in Healthy volunteers in USA (NCT02447458)